Department of Anesthesiology, Erasme University Hospital, Brussels, Belgium.
J Cardiothorac Vasc Anesth. 2010 Aug;24(4):608-16. doi: 10.1053/j.jvca.2009.10.006. Epub 2009 Dec 16.
To investigate the relationships between 2 anesthetic techniques, or the extent of allodynia around the surgical wound, and the occurrence of chronic post-thoracotomy pain.
Prospective, randomized study.
A single-institution, university hospital.
Thirty-eight patients who underwent elective thoracotomy under general anesthesia.
High-dose remifentanil (average effect-site concentration 5.61 +/- 0.84 ng/mL) with epidural analgesia started and at the end of surgery or low-dose remifentanil (average effect site concentration 1.99 +/- 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia.
Pain intensity and the extent of allodynia around the wound were measured during the hospital stay. The presence and intensity of residual pain were assessed 1, 3, and 6 months after surgery and at the end of the study (6-13 months, average 9 months). A DN4 neuropathic pain diagnostic questionnaire was conducted at the same times. In the high-dose group, the area with allodynia was three times larger than the area in the low-dose group. The increased allodynia was associated with a higher incidence of chronic pain (RR: 2.7-4.2) 3 and 6 months after surgery and at the end of the study (median follow-up: 9.5 months).
High-dose remifentanil (0.14-0.26 microg/kg/min) without epidural analgesia during surgery is associated with a large area of allodynia around the wound. These patients develop a much higher incidence of chronic pain than those receiving low-dose remifentanil with epidural analgesia during surgery.
探讨两种麻醉技术之间的关系,即手术切口周围的痛觉过敏程度与慢性开胸术后疼痛的发生之间的关系。
前瞻性、随机研究。
一家机构、大学医院。
38 名在全身麻醉下接受择期开胸手术的患者。
高剂量瑞芬太尼(平均效应部位浓度 5.61 +/- 0.84 ng/mL)加硬膜外镇痛,在手术开始和结束时;或低剂量瑞芬太尼(平均效应部位浓度 1.99 +/- 0.02 ng/mL)加硬膜外镇痛,在麻醉开始时用 0.5%罗哌卡因。
在住院期间测量疼痛强度和伤口周围痛觉过敏的程度。术后 1、3 和 6 个月以及研究结束时(6-13 个月,平均 9 个月)评估残留疼痛的存在和强度。同时进行了 DN4 神经性疼痛诊断问卷。在高剂量组,痛觉过敏的面积是低剂量组的三倍。痛觉过敏的增加与慢性疼痛的发生率较高有关(RR:2.7-4.2),术后 3 个月和 6 个月以及研究结束时(中位数随访:9.5 个月)。
术中不使用硬膜外镇痛给予高剂量瑞芬太尼(0.14-0.26 microg/kg/min)与伤口周围大面积痛觉过敏有关。这些患者发生慢性疼痛的发生率明显高于术中接受低剂量瑞芬太尼加硬膜外镇痛的患者。